These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 36613762)
1. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762 [TBL] [Abstract][Full Text] [Related]
2. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition. Lin X; Soni A; Hessenow R; Sun Y; Mladenov E; Guberina M; Stuschke M; Iliakis G Radiother Oncol; 2024 Nov; 200():110475. PubMed ID: 39147034 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells. Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557 [TBL] [Abstract][Full Text] [Related]
13. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis. Gelot C; Kovacs MT; Miron S; Mylne E; Haan A; Boeffard-Dosierre L; Ghouil R; Popova T; Dingli F; Loew D; Guirouilh-Barbat J; Del Nery E; Zinn-Justin S; Ceccaldi R Nature; 2023 Sep; 621(7978):415-422. PubMed ID: 37674080 [TBL] [Abstract][Full Text] [Related]
14. Targeting Polymerase Theta (POLθ) for Cancer Therapy. Patterson-Fortin J; D'Andrea AD Cancer Treat Res; 2023; 186():285-298. PubMed ID: 37978141 [TBL] [Abstract][Full Text] [Related]
15. PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks. Vekariya U; Minakhin L; Chandramouly G; Tyagi M; Kent T; Sullivan-Reed K; Atkins J; Ralph D; Nieborowska-Skorska M; Kukuyan AM; Tang HY; Pomerantz RT; Skorski T Nat Commun; 2024 Jul; 15(1):5822. PubMed ID: 38987289 [TBL] [Abstract][Full Text] [Related]
16. POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis. Llorens-Agost M; Ensminger M; Le HP; Gawai A; Liu J; Cruz-García A; Bhetawal S; Wood RD; Heyer WD; Löbrich M Nat Cell Biol; 2021 Oct; 23(10):1095-1104. PubMed ID: 34616022 [TBL] [Abstract][Full Text] [Related]
17. The helicase domain of Polθ counteracts RPA to promote alt-NHEJ. Mateos-Gomez PA; Kent T; Deng SK; McDevitt S; Kashkina E; Hoang TM; Pomerantz RT; Sfeir A Nat Struct Mol Biol; 2017 Dec; 24(12):1116-1123. PubMed ID: 29058711 [TBL] [Abstract][Full Text] [Related]
18. Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks. Murmann-Konda T; Soni A; Stuschke M; Iliakis G Mutat Res Genet Toxicol Environ Mutagen; 2021 Jul; 867():503372. PubMed ID: 34266628 [TBL] [Abstract][Full Text] [Related]